Recent Updates
Recently added Catalysts

DCDT2980S

Phase 1

Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | Small molecule | Oncology |Roche Holding AG|Last Updated: Nov 2, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment91

FDA Designations

No designations recorded

Clinical trial landscape

DCDT2980S · 1 trial · 1 indication

Phase 1 1
NCT01209130A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's LymphomaNon-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
COMPLETED91 Analytics
PHASE1COMPLETED
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
NCT0120913091
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence and nature of dose-limiting toxicities (DLTs)
Throughout study or until early discontinuation

Secondary Endpoints

Objective response, defined as a partial response (PR) or complete response (CR)
Throughout study or until early discontinuation
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
AEXPERIMENTAL -
BEXPERIMENTAL -

Interventions

NameTypeDescription
DCDT2980SDRUGIntravenous repeating dose
rituximabDRUGIntravenous repeating dose
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites9

Inclusion Criteria: * Life expectancy of at least 12 weeks * History of histologically-documented hematologic malignancy for which no effective standard therapy exists: indolent NHL (including Grades 1-3a FL; MZL \[including splenic, nodal, and extra-nodal\]; and SLL), Grade 3b FL, DLBCL, MCL, or C...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about DCDT2980S

What is DCDT2980S used for?

DCDT2980S is an investigational oncology drug being studied for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. It is a small molecule therapeutic developed by Roche Holding AG and is currently in Phase 1 clinical development.

Who makes DCDT2980S?

DCDT2980S is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is an investigational small molecule in Phase 1 clinical development for oncology indications, specifically Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.

What phase is DCDT2980S in?

DCDT2980S is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.

What clinical trials is DCDT2980S in?

DCDT2980S has been studied in one completed Phase 1 clinical trial, identified as NCT01209130. This trial evaluated the safety and pharmacokinetics of escalating doses of DCDT2980S in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, including combination therapy with rituximab.

Is DCDT2980S FDA approved?

DCDT2980S is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. The drug has completed one clinical trial, but it remains under investigation and has not received regulatory approval.